

Anders Svenningsson

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/7498260/publications.pdf>

Version: 2024-02-01

95
papers

6,233
citations

101384

36
h-index

71532

76
g-index

96
all docs

96
docs citations

96
times ranked

6520
citing authors

#	ARTICLE	IF	CITATIONS
1	Diagnostic Value of Cerebrospinal Fluid Neurofilament Light Protein in Neurology. <i>JAMA Neurology</i> , 2019, 76, 1035.	4.5	455
2	Infection Risks Among Patients With Multiple Sclerosis Treated With Fingolimod, Natalizumab, Rituximab, and Injectable Therapies. <i>JAMA Neurology</i> , 2020, 77, 184.	4.5	342
3	Monitoring disease activity in multiple sclerosis using serum neurofilament light protein. <i>Neurology</i> , 2017, 89, 2230-2237.	1.5	307
4	Axonal damage in relapsing multiple sclerosis is markedly reduced by natalizumab. <i>Annals of Neurology</i> , 2011, 69, 83-89.	2.8	295
5	Neuroprotection by Encephalomyelitis: Rescue of Mechanically Injured Neurons and Neurotrophin Production by CNS-Infiltrating T and Natural Killer Cells. <i>Journal of Neuroscience</i> , 2000, 20, 5283-5291.	1.7	293
6	Rituximab in multiple sclerosis. <i>Neurology</i> , 2016, 87, 2074-2081.	1.5	278
7	An altered immune response to Epstein-Barr virus in multiple sclerosis. <i>Neurology</i> , 2004, 62, 2277-2282.	1.5	272
8	Timing of high-efficacy therapy for multiple sclerosis: a retrospective observational cohort study. <i>Lancet Neurology</i> , The, 2020, 19, 307-316.	4.9	219
9	Neurofilament and glial fibrillary acidic protein in multiple sclerosis. <i>Neurology</i> , 2004, 63, 1586-1590.	1.5	199
10	Rituximab versus fingolimod after natalizumab in multiple sclerosis patients. <i>Annals of Neurology</i> , 2016, 79, 950-958.	2.8	190
11	Neurofilament light as a prognostic marker in multiple sclerosis. <i>Multiple Sclerosis Journal</i> , 2010, 16, 287-292.	1.4	162
12	Comparative Effectiveness of Rituximab and Other Initial Treatment Choices for Multiple Sclerosis. <i>JAMA Neurology</i> , 2018, 75, 320.	4.5	155
13	Autologous haematopoietic stem cell transplantation for aggressive multiple sclerosis: the Swedish experience. <i>Journal of Neurology, Neurosurgery and Psychiatry</i> , 2014, 85, 1116-1121.	0.9	139
14	Neurofilament light in CSF and serum is a sensitive marker for axonal white matter injury in MS. <i>Neurology: Neuroimmunology and Neuroinflammation</i> , 2016, 3, e271.	3.1	118
15	Adhesion molecule expression on cerebrospinal fluid T lymphocytes: Evidence for common recruitment mechanisms in multiple sclerosis, aseptic meningitis, and normal controls. <i>Annals of Neurology</i> , 1993, 34, 155-161.	2.8	114
16	Comparative Assessment of the Prognostic Value of Biomarkers in Traumatic Brain Injury Reveals an Independent Role for Serum Levels of Neurofilament Light. <i>PLoS ONE</i> , 2015, 10, e0132177.	1.1	114
17	Lymphocyte phenotype and subset distribution in normal cerebrospinal fluid. <i>Journal of Neuroimmunology</i> , 1995, 63, 39-46.	1.1	110
18	Linomide reduces the rate of active lesions in relapsing-remitting multiple sclerosis. <i>Neurology</i> , 1996, 47, 895-900.	1.5	101

#	ARTICLE	IF	CITATIONS
19	Immunosuppressive therapy reduces axonal damage in progressive multiple sclerosis. <i>Multiple Sclerosis Journal</i> , 2014, 20, 43-50.	1.4	101
20	A Swedish national post-marketing surveillance study of natalizumab treatment in multiple sclerosis. <i>Multiple Sclerosis Journal</i> , 2011, 17, 708-719.	1.4	98
21	Levels and Age Dependency of Neurofilament Light and Glial Fibrillary Acidic Protein in Healthy Individuals and Their Relation to the Brain Parenchymal Fraction. <i>PLoS ONE</i> , 2015, 10, e0135886.	1.1	97
22	NORdic trial of oral Methylprednisolone as add-on therapy to Interferon beta-1a for treatment of relapsing-remitting Multiple Sclerosis (NORMIMS study): a randomised, placebo-controlled trial. <i>Lancet Neurology</i> , The, 2009, 8, 519-529.	4.9	95
23	Incidence of MS during two fifteen-year periods in the Gothenburg region of Sweden. <i>Acta Neurologica Scandinavica</i> , 1990, 82, 161-168.	1.0	91
24	Natalizumab Treatment Reduces Fatigue in Multiple Sclerosis. Results from the TYNERGY Trial; A Study in the Real Life Setting. <i>PLoS ONE</i> , 2013, 8, e58643.	1.1	91
25	Treatment Escalation vs Immediate Initiation of Highly Effective Treatment for Patients With Relapsing-Remitting Multiple Sclerosis. <i>JAMA Neurology</i> , 2021, 78, 1197.	4.5	90
26	Cancer Risk for Fingolimod, Natalizumab, and Rituximab in Multiple Sclerosis Patients. <i>Annals of Neurology</i> , 2020, 87, 688-699.	2.8	86
27	Natalizumab exerts a suppressive effect on surrogates of B cell function in blood and CSF. <i>Multiple Sclerosis Journal</i> , 2015, 21, 1036-1044.	1.4	78
28	Reduced inflammation in relapsing-remitting multiple sclerosis after therapy switch to rituximab. <i>Neurology</i> , 2016, 87, 141-147.	1.5	74
29	Intense Inflammation and Nerve Damage in Early Multiple Sclerosis Subsides at Older Age: A Reflection by Cerebrospinal Fluid Biomarkers. <i>PLoS ONE</i> , 2013, 8, e63172.	1.1	69
30	Lipocalin-2 is increased in progressive multiple sclerosis and inhibits remyelination. <i>Neurology: Neuroimmunology and Neuroinflammation</i> , 2016, 3, e191.	3.1	69
31	Efficacy and Safety of the Dopaminergic Stabilizer Pridopidine (ACR16) in Patients With Huntington's Disease. <i>Clinical Neuropharmacology</i> , 2010, 33, 260-264.	0.2	65
32	Guidelines for the use of magnetic resonance imaging in diagnosing and monitoring the treatment of multiple sclerosis: recommendations of the Swedish Multiple Sclerosis Association and the Swedish Neuroradiological Society. <i>Acta Neurologica Scandinavica</i> , 2017, 135, 17-24.	1.0	57
33	Differential Expression of Neurotrophic Factors and Inflammatory Cytokines by Myelin Basic Protein-Specific and Other Recruited T Cells Infiltrating the Central Nervous System during Experimental Autoimmune Encephalomyelitis. <i>Scandinavian Journal of Immunology</i> , 2002, 55, 264-273.	1.3	51
34	Automated Determination of Brain Parenchymal Fraction in Multiple Sclerosis. <i>American Journal of Neuroradiology</i> , 2013, 34, 498-504.	1.2	51
35	Humoral immune response to influenza vaccine in natalizumab-treated MS patients. <i>Neurological Research</i> , 2012, 34, 730-733.	0.6	50
36	Safety and efficacy of rituximab versus dimethyl fumarate in patients with relapsing-remitting multiple sclerosis or clinically isolated syndrome in Sweden: a rater-blinded, phase 3, randomised controlled trial. <i>Lancet Neurology</i> , The, 2022, 21, 693-703.	4.9	45

#	ARTICLE	IF	CITATIONS
37	Rituximab in paediatric onset multiple sclerosis: a case series. <i>Journal of Neurology</i> , 2016, 263, 322-326.	1.8	42
38	Vitamin D and axonal injury in multiple sclerosis. <i>Multiple Sclerosis Journal</i> , 2016, 22, 1027-1031.	1.4	39
39	Season of birth and multiple sclerosis in Sweden. <i>Acta Neurologica Scandinavica</i> , 2010, 121, 20-23.	1.0	38
40	Rapid depletion of B lymphocytes by ultra-low-dose rituximab delivered intrathecally. <i>Neurology: Neuroimmunology and NeuroInflammation</i> , 2015, 2, e79.	3.1	38
41	Increased expression of B7-1 costimulatory molecule on cerebrospinal fluid cells of patients with multiple sclerosis and infectious central nervous system disease. <i>Journal of Neuroimmunology</i> , 1997, 75, 59-68.	1.1	36
42	Improvement in Fatigue during Natalizumab Treatment is Linked to Improvement in Depression and Day-Time Sleepiness. <i>Frontiers in Neurology</i> , 2015, 6, 18.	1.1	36
43	Nitric oxide metabolites in CSF of patients with MS are related to clinical disease course. <i>Neurology</i> , 1999, 53, 1880-1880.	1.5	36
44	Simultaneous detection of ferritin and HIV-1 in reactive microglia. <i>Acta Neuropathologica</i> , 1992, 84, 297-306.	3.9	33
45	Cerebrospinal fluid biomarkers of inflammation in trigeminal neuralgia patients operated with microvascular decompression. <i>Pain</i> , 2019, 160, 2603-2611.	2.0	33
46	Intrathecal treatment trial of rituximab in progressive MS. <i>Neurology</i> , 2018, 91, e1893-e1901.	1.5	32
47	Antibody-mediated suppression of V α 2.2/5.3+T cells in multiple sclerosis: Results from an MRI-monitored phase II clinical trial. <i>Annals of Neurology</i> , 2002, 51, 467-474.	2.8	30
48	Molecular and genetic requirements for preferential recruitment of TCRBV8S2+ T cells in Lewis rat experimental autoimmune encephalomyelitis. <i>Journal of Immunology</i> , 1998, 160, 681-90.	0.4	30
49	Brain Parenchymal Fraction in Healthy Adults – A Systematic Review of the Literature. <i>PLoS ONE</i> , 2017, 12, e0170018.	1.1	29
50	Fatal neuroinflammation in a case of multiple sclerosis with anti-natalizumab antibodies. <i>Neurology</i> , 2013, 80, 965-967.	1.5	28
51	Natalizumab, rituximab and fingolimod as escalation therapy in multiple sclerosis. <i>European Journal of Neurology</i> , 2019, 26, 1060-1067.	1.7	27
52	The cerebrospinal fluid cytokine signature of multiple sclerosis: A homogenous response that does not conform to the Th1/Th2/Th17 convention. <i>Journal of Neuroimmunology</i> , 2014, 277, 153-159.	1.1	26
53	Cerebrospinal fluid concentration of Galectin-9 is increased in secondary progressive multiple sclerosis. <i>Journal of Neuroimmunology</i> , 2016, 292, 40-44.	1.1	26
54	Population-based cohort study on the epidemiology of acute appendicitis in children in Sweden in 1987-2013. <i>BJS Open</i> , 2018, 2, 142-150.	0.7	26

#	ARTICLE	IF	CITATIONS
55	Sick leave and professional assistance for multiple sclerosis individuals in VÄsterbotten County, northern Sweden. <i>Multiple Sclerosis Journal</i> , 2003, 9, 515-520.	1.4	24
56	Improved ability to work after one year of natalizumab treatment in multiple sclerosis. Analysis of disease-specific and work-related factors that influence the effect of treatment. <i>Multiple Sclerosis Journal</i> , 2013, 19, 622-630.	1.4	22
57	Effect of Treatment with Natalizumab on Ability to Work in People with Multiple Sclerosis. <i>BioDrugs</i> , 2011, 25, 299-306.	2.2	21
58	Comparison of plasma and cerebrospinal fluid neurofilament light in a multiple sclerosis trial. <i>Acta Neurologica Scandinavica</i> , 2019, 139, 462-468.	1.0	21
59	Improved treatment satisfaction after switching therapy to rituximab in relapsing-remitting MS. <i>Multiple Sclerosis Journal</i> , 2017, 23, 1249-1257.	1.4	20
60	NFL and CXCL13 may reveal disease activity in clinically and radiologically stable MS. <i>Multiple Sclerosis and Related Disorders</i> , 2020, 46, 102463.	0.9	20
61	Age-dependent effects on the treatment response of natalizumab in MS patients. <i>Multiple Sclerosis Journal</i> , 2015, 21, 48-56.	1.4	19
62	Brain parenchymal fraction in an age-stratified healthy population—determined by MRI using manual segmentation and three automated segmentation methods. <i>Journal of Neuroradiology</i> , 2016, 43, 384-391.	0.6	18
63	Targeted metabolomics of CSF in healthy individuals and patients with secondary progressive multiple sclerosis using high-resolution mass spectrometry. <i>Metabolomics</i> , 2020, 16, 26.	1.4	18
64	Increasing prevalence of multiple sclerosis in VÄsterbotten County of Sweden. <i>Acta Neurologica Scandinavica</i> , 2015, 132, 389-394.	1.0	16
65	Prevention of post-dural puncture headache: a randomized controlled trial. <i>European Journal of Neurology</i> , 2020, 27, 871-877.	1.7	15
66	Metabolomics of Cerebrospinal Fluid from Healthy Subjects Reveal Metabolites Associated with Ageing. <i>Metabolites</i> , 2021, 11, 126.	1.3	15
67	Differential regulation of macrophage scavenger receptor isoforms: mRNA quantification using the polymerase chain reaction. <i>Journal of Lipid Research</i> , 1995, 36, 2282-90.	2.0	15
68	HIV-1 in postmortem brain tissue from patients with AIDS. <i>Aids</i> , 1992, 6, 915-924.	1.0	13
69	No evidence for spumavirus or oncovirus infection in relapsing-remitting multiple sclerosis. <i>Annals of Neurology</i> , 1992, 32, 711-714.	2.8	13
70	Immunological profile in cerebrospinal fluid of patients with multiple sclerosis after treatment switch to rituximab and compared with healthy controls. <i>PLoS ONE</i> , 2018, 13, e0192516.	1.1	13
71	Identification and analysis of macrophage-derived foam cells from human atherosclerotic lesions by using a mock FL3 channel in flow cytometry. , 1997, 29, 155-164.		12
72	Reduced sick leave in multiple sclerosis after one year of natalizumab treatment. A prospective ad hoc analysis of the TYNERGY trial. <i>Multiple Sclerosis Journal</i> , 2014, 20, 1095-1101.	1.4	12

#	ARTICLE	IF	CITATIONS
73	HIV-1 propagates in human neuroblastoma cells. <i>Journal of Acquired Immune Deficiency Syndromes</i> , 1991, 4, 228-37.	1.0	12
74	Human spumaretrovirus antibody reactivity in multiple sclerosis. <i>Journal of Neurology</i> , 1994, 241, 204-209.	1.8	11
75	Reduced Frequency of Memory CD8 ⁺ T Lymphocytes in Cerebrospinal Fluid and Blood of Patients with Multiple Sclerosis. <i>Autoimmunity</i> , 1995, 21, 231-239.	1.2	11
76	Intra-CNS activation by antigen-specific T lymphocytes in experimental autoimmune encephalomyelitis. <i>Journal of Neuroimmunology</i> , 2001, 113, 202-211.	1.1	11
77	Inflammatory activity and vitamin D levels in an MS population treated with rituximab. <i>Multiple Sclerosis Journal - Experimental, Translational and Clinical</i> , 2019, 5, 205521731982659.	0.5	11
78	Serum sickness following rituximab therapy in multiple sclerosis. <i>Neurology: Clinical Practice</i> , 2019, 9, 519-521.	0.8	10
79	Comparative effectiveness of dimethyl fumarate as the initial and secondary treatment for MS. <i>Multiple Sclerosis Journal</i> , 2020, 26, 1532-1539.	1.4	8
80	HIV-1 infection of CD4-negative cells via HTLV pseudovirions. <i>Aids</i> , 1991, 5, 769-771.	1.0	7
81	Possible association of HTLV-I infection and dementia. <i>Acta Neurologica Scandinavica</i> , 2009, 88, 199-203.	1.0	7
82	Measurement of sCD27 in the cerebrospinal fluid identifies patients with neuroinflammatory disease. <i>Journal of Neuroimmunology</i> , 2019, 332, 31-36.	1.1	7
83	Intrathecal treatment trial of rituximab in progressive MS: results after a 2-year extension. <i>Journal of Neurology</i> , 2021, 268, 651-657.	1.8	6
84	Lumbar puncture preferences among Swedish neurologists. <i>Neurological Research</i> , 2015, 37, 92-94.	0.6	4
85	Cell Adhesion Molecules in Multiple Sclerosis. <i>CNS Drugs</i> , 1994, 2, 87-95.	2.7	3
86	Serum neurofilament light and prediction of multiple sclerosis in clinically isolated syndrome. <i>Neurology</i> , 2019, 92, 313-314.	1.5	3
87	Improved working ability in a contemporary MS population compared with a historic non-treated MS population in the same geographic area of Sweden. <i>Multiple Sclerosis Journal - Experimental, Translational and Clinical</i> , 2015, 1, 205521731560820.	0.5	2
88	Lower risk of multiple sclerosis in patients with chronic hepatitis C: a nationwide population-based registry study. <i>Journal of Neurology</i> , 2019, 266, 2208-2215.	1.8	2
89	How to minimize the risk for headache? A lumbar puncture practice questionnaire study = Hogyan csökkenthetők a posztpunkciós fejfájás? Kérdéses vizsgálat a lumbálpunkciós gyakorlatról. <i>Ideggyógyászati Szemle</i> , 2016, 69, 397-402.	0.4	2
90	Linomide reduces the rate of active lesions in relapsing-remitting multiple sclerosis. <i>Journal of Neuroimmunology</i> , 1995, 56-63, 26-26.	1.1	0

#	ARTICLE	IF	CITATIONS
91	Reply. <i>Annals of Neurology</i> , 2016, 80, 791-792.	2.8	0
92	Cortico-juxtacortical and periventricular lesions and MS diagnostic criteria. <i>Neurology</i> , 2017, 89, 2308-2309.	1.5	0
93	Reply to Sun et al.. <i>Pain</i> , 2019, 160, 2898-2899.	2.0	0
94	Clinical, Biochemical and Imaging Parameters that may be Predictive of High Disease Activity, Rapid Progression or Increased Disability in Multiple Sclerosis. <i>European Neurological Review</i> , 2013, 8, 10.	0.5	0
95	Long-term treatment with anti-CD20 monoclonal antibodies is untenable because of risk: Commentary. <i>Multiple Sclerosis Journal</i> , 2022, 28, 1177-1178.	1.4	0